Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Karas, Michal
HALF, NCT04147533: Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia	Active, not recruiting	2	150	RoW	Imatinib withdrawal, Glivec withdrawal, Dasatinib, Sprycel withdrawal, Nilotinib, Tasigna withdrawal	Masaryk University	Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug	06/26	06/26